Male and female Lilly scientists smiling in a laboratory. Male and female Lilly scientists smiling in a laboratory.

Lilly Alzheimer’s Disease Research

Lilly has been a leader in Alzheimer’s disease research for over 30 years. This would not have been possible without research study volunteers like you.

expand_more Start Here arrow_downward

70 research studies

23,726 participants

Research studies and participants in Alzheimer’s disease and mild cognitive impairment (MCI) research studies conducted by Lilly. info

Male and female researchers studying in a clinical setting. Male and female researchers studying in a clinical setting.

Lilly's Commitment to Alzheimer's Research

Alzheimer’s is such a complex disease that our research must be both determined and persistent. Scientists at Eli Lilly and Company have studied the complicated biology of Alzheimer’s disease for over 30 years. Their discoveries have helped shape the development of drugs being researched today. In 2017, Lilly presented findings from nearly 40 studies at the Alzheimer’s Association annual conference.

We now understand more about how Alzheimer’s disease may develop in the brain. We have research studies testing investigational drugs to see whether they may slow or stop the development of Alzheimer’s. What’s more, we are now testing new ways to see changes in the brain. This may help speed up research by helping us to find the right volunteers more quickly.

Next Section arrow_downward
Three cheerful people meeting in an informal conference room. Three cheerful people meeting in an informal conference room.

Collaborations: Lilly's Alzheimer's Research

Lilly’s research often involves teamwork with other parties that share our passion for finding effective treatments for Alzheimer's disease. We work with academic institutions, government entities, and advocacy organizations. This work enables us to harness scientific breakthroughs and the latest knowledge about the disease. Through these collaborations, we discover together.

Our collaborative research studies include:


Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Research Study

The A4 research study examines whether a study drug targeting beta amyloid can help slow memory loss in some people. The research involves people who do not have symptoms of Alzheimer’s disease but do already have an increased number of brain plaques. These plaques are a potential sign of Alzheimer’s disease. The A4 research study is funded by the National Institute on Aging and Lilly, as well as several philanthropic organizations.


Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Research Study

The DIAN-TU research study is a global research partnership studying a rare form of Alzheimer’s disease that runs in families. It is researching two study drugs that target beta amyloid. The National Institutes of Health, philanthropic contributions, Lilly, and Roche funded this research study.

Researcher investigating something up close. Researcher investigating something up close.

The Science: Lilly’s Alzheimer’s Research

Lilly is studying many investigational drugs and imaging tools in Alzheimer’s research studies. Many of these study drugs are intended to target beta amyloid and tau. Beta amyloid and tau are pieces of protein, and may be biomarkers for Alzheimer’s disease. A biomarker is also called a marker or indicator. It is a measurable sign of some state or condition. For example, cholesterol level is a biomarker for coronary artery disease. Similarly, beta amyloid and abnormal tau proteins may be biomarkers for Alzheimer’s disease. We are also studying imaging tools that may help researchers see these markers in the brain.

Next Section arrow_downward
"I’d like to find something [that] could stop it [Alzheimer’s] from getting worse, and find out what’s causing it." Nola


Share this page:

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.